VISUDYNE® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular...

Apr 14, 2026 · VISUDYNE ® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular …

Aug 27, 2025 · VISUDYNE ® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular …

Apr 12, 2000 · Visudyne is a brand name of verteporfin, approved by the FDA in the following formulation: Has a generic version of Visudyne been approved? No, the FDA has not approved a …

List of Approved Drug Products containing Verteporfin (Visudyne) in the FDA Orange Book on PharmaCompass.com

Detailed FDA approval information for Visudyne, including regulatory status, product details, and official drug labeling information.

1.1 Content and Exclusion The Orange Book is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations (Prescription Drug Product List) ; (2) approved …

Jun 13, 2005 · Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative comprising a 50:50 mixture of two isomers: CL-315555 and CL-315585. It is used as a photosensitizer in photodynamic …

VISUDYNE® is administered through an infusion into the patient’s arm. The drug then circulates throughout the body; the abnormal vessels in the patient’s eye attract and absorb the drug.

Visudyne, otherwise known as benzoporphyrin derivative (trade name Visudyne®), is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye …